CYP.AX
Price:
$0.23
Market Cap:
$51.81M
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, ...[Read more]
Industry
Biotechnology
IPO Date
2007-12-19
Stock Exchange
ASX
Ticker
CYP.AX
According to Cynata Therapeutics Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 45.60M. This represents a change of 110.17% compared to the average of 21.70M of the last 4 quarters.
The mean historical Enterprise Value of Cynata Therapeutics Limited over the last ten years is 50.38M. The current 45.60M Enterprise Value has changed 8.95% with respect to the historical average. Over the past ten years (40 quarters), CYP.AX's Enterprise Value was at its highest in in the June 2019 quarter at 119.36M. The Enterprise Value was at its lowest in in the June 2009 quarter at -1005023.00.
Average
50.38M
Median
42.97M
Minimum
1.97M
Maximum
118.29M
Discovering the peaks and valleys of Cynata Therapeutics Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.28%
Maximum Annual Enterprise Value = 118.29M
Minimum Annual Increase = -92.91%
Minimum Annual Enterprise Value = 1.97M
Year | Enterprise Value | Change |
---|---|---|
2024 | 46.79M | 2.28% |
2023 | 1.97M | -92.91% |
2022 | 27.78M | -29.04% |
2021 | 39.15M | -21.86% |
2020 | 50.10M | -57.64% |
2019 | 118.29M | 5.76% |
2018 | 111.84M | 189.50% |
2017 | 38.63M | 118.93% |
2016 | 17.65M | -65.78% |
2015 | 51.57M | 298.62% |
The current Enterprise Value of Cynata Therapeutics Limited (CYP.AX) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
25.51M
5-year avg
33.16M
10-year avg
50.38M
Cynata Therapeutics Limited’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cynata Therapeutics Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cynata Therapeutics Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Cynata Therapeutics Limited's Enterprise Value?
What is the highest Enterprise Value for Cynata Therapeutics Limited (CYP.AX)?
What is the 3-year average Enterprise Value for Cynata Therapeutics Limited (CYP.AX)?
What is the 5-year average Enterprise Value for Cynata Therapeutics Limited (CYP.AX)?
How does the current Enterprise Value for Cynata Therapeutics Limited (CYP.AX) compare to its historical average?